Immacolata Prevenzano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Immacolata Prevenzano has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Miele
URT Genomics of Diabetes, Institute of Experimental Endocrinology and Oncology, National Research Council, Naples, Italy
3 shared publications - Francesco Beguinot
Department of Translational Medicine, Federico II University of Naples, Naples, Italy
3 shared publications - Michele Longo
Department of Translational Medicine, Federico II University of Naples, Naples, Italy
2 shared publications - Alessandra Croce
Department of Translational Medical Sciences University of Naples Federico II Naples Italy
1 shared publication - Alessia Leone
URT of the Institute of Experimental Endocrinology and Oncology "G. Salvatore", National Council of Research, Naples, Italy; Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy
1 shared publication - Antonella Desiderio
URT Genomics of Diabetes, Institute of Experimental Endocrinology and Oncology, National Research Council, Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 7 March 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (5) , e71639
Methylglyoxal Affects Dopamine Homeostasis in SH‐SY5Y Cells Through the Modulation of miR‐190a and miR‐214
Dopamine (DA) homeostasis is crucial for several relevant body functions, including cognition. Diabetes mellitus (DM) is characterized by both cognitive decline and dopaminergic dysfunction. Methylglyoxal (MGO), a reactive neurotoxic dicarbonyl, which accumulates in DM, induces dopaminergic dysfunction, contributing to DA depletion, and is associated with cognitive deficit. However, the molecular mechanisms underlying MGO impact on dopaminergic function are still unknown. This study aims to clarify how MGO damages the dopaminergic system, analyzing the contribution of miRNAs in its deleterious effect in SH‐SY5Y cells. We found that treatment with MGO significantly reduces the intracellular DA content, increasing the expression of proteins known to negatively affect DA amount, such as COMT (Catechol‐O‐methyltransferase), MAO (Monoamine oxidase), and α‐Syn (α‐synuclein), encoded by the SNCA gene. This was paralleled by a significant reduction in the expression of miR‐190a and miR‐214, known to be regulated by MGO in other cellular models. We found, by TARGETSCAN analysis, that these two miRNAs are predicted regulators of COMT and SNCA. Gain‐ and loss‐of‐function experiments highlighted that these miRNAs are able to modulate the expression of these proteins. We also showed that COMT is a direct target of both miR‐190a and miR‐214, while SNCA is a direct target of miR‐190a and an indirect target for miR‐214. Importantly, the transfection of miR‐190a and miR‐214 specific mimics reverted MGO effects on COMT and α‐Syn expression and restored DA intracellular content. Thus, these miRNAs could represent innovative pharmacological targets for the treatment of DM‐associated dopaminergic dysfunction and cognitive decline.
- 7 March 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (5) , e71639
Open AccessMethylglyoxal Affects Dopamine Homeostasis in SH‐SY5Y Cells Through the Modulation of miR‐190a and miR‐214
Dopamine (DA) homeostasis is crucial for several relevant body functions, including cognition. Diabetes mellitus (DM) is characterized by both cognitive decline and dopaminergic dysfunction. Methylglyoxal (MGO), a reactive neurotoxic dicarbonyl, which accumulates in DM, induces dopaminergic dysfunction, contributing to DA depletion, and is associated with cognitive deficit. However, the molecular mechanisms underlying MGO impact on dopaminergic function are still unknown. This study aims to clarify how MGO damages the dopaminergic system, analyzing the contribution of miRNAs in its deleterious effect in SH‐SY5Y cells. We found that treatment with MGO significantly reduces the intracellular DA content, increasing the expression of proteins known to negatively affect DA amount, such as COMT (Catechol‐O‐methyltransferase), MAO (Monoamine oxidase), and α‐Syn (α‐synuclein), encoded by the SNCA gene. This was paralleled by a significant reduction in the expression of miR‐190a and miR‐214, known to be regulated by MGO in other cellular models. We found, by TARGETSCAN analysis, that these two miRNAs are predicted regulators of COMT and SNCA. Gain‐ and loss‐of‐function experiments highlighted that these miRNAs are able to modulate the expression of these proteins. We also showed that COMT is a direct target of both miR‐190a and miR‐214, while SNCA is a direct target of miR‐190a and an indirect target for miR‐214. Importantly, the transfection of miR‐190a and miR‐214 specific mimics reverted MGO effects on COMT and α‐Syn expression and restored DA intracellular content. Thus, these miRNAs could represent innovative pharmacological targets for the treatment of DM‐associated dopaminergic dysfunction and cognitive decline.
- Open Access
- 7 October 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (19) , e70093
Hypomethylation at PANDAR promoter progressively induces senescence in adipocyte precursor cells in subjects with obesity and type 2 diabetes
The risk of developing type 2 diabetes (T2D) is heterogeneous among individuals with obesity. Functional decline of adipocyte precursor cells (APCs) and accumulation of senescent cells in the subcutaneous adipose tissue contributes to the progression toward T2D. LncRNAs regulate cell senescence and may be implicated in determining this abnormality in APCs. Here, we report that APCs from individuals with obesity show a gradual increase in multiple senescence markers, which worsens in parallel with the progression from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) or T2D. Transcriptomic analysis identified PANDAR as the top‐ranked lncRNA differentially expressed in APCs from individuals with obesity and T2D and non‐obese subjects. Q‐PCR confirmed PANDAR up‐regulation in APCs from individuals with obesity, at progressively increased levels in those who developed, respectively, IGT and T2D. Bisulfite sequencing and luciferase assays revealed that, in parallel with glucose tolerance deterioration, the −1317 CpG at the PANDAR promoter became hypo‐methylated in obesity, resulting in enhanced PANDAR induction by p53. PANDAR silencing in senescent APCs from individuals with obesity and T2D caused repression of senescence programs and cell cycle re‐entry. PANDAR transcription in white blood cells (WBCs) mirrored that in APCs. Also, individuals with obesity exhibited rescue of PANDAR transcription in WBCs following bariatric surgery, accompanied by enhanced methylation at the regulatory PANDAR −1317 CpG. In conclusion, PANDAR dysregulation is a newly identified mechanism determining the early senescence of APCs from individuals with obesity, which worsens along the progression toward T2D. In the future, PANDAR targeting may represent a valuable strategy to delay this progression.
- 7 October 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (19) , e70093
Open AccessHypomethylation at PANDAR promoter progressively induces senescence in adipocyte precursor cells in subjects with obesity and type 2 diabetes
The risk of developing type 2 diabetes (T2D) is heterogeneous among individuals with obesity. Functional decline of adipocyte precursor cells (APCs) and accumulation of senescent cells in the subcutaneous adipose tissue contributes to the progression toward T2D. LncRNAs regulate cell senescence and may be implicated in determining this abnormality in APCs. Here, we report that APCs from individuals with obesity show a gradual increase in multiple senescence markers, which worsens in parallel with the progression from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) or T2D. Transcriptomic analysis identified PANDAR as the top‐ranked lncRNA differentially expressed in APCs from individuals with obesity and T2D and non‐obese subjects. Q‐PCR confirmed PANDAR up‐regulation in APCs from individuals with obesity, at progressively increased levels in those who developed, respectively, IGT and T2D. Bisulfite sequencing and luciferase assays revealed that, in parallel with glucose tolerance deterioration, the −1317 CpG at the PANDAR promoter became hypo‐methylated in obesity, resulting in enhanced PANDAR induction by p53. PANDAR silencing in senescent APCs from individuals with obesity and T2D caused repression of senescence programs and cell cycle re‐entry. PANDAR transcription in white blood cells (WBCs) mirrored that in APCs. Also, individuals with obesity exhibited rescue of PANDAR transcription in WBCs following bariatric surgery, accompanied by enhanced methylation at the regulatory PANDAR −1317 CpG. In conclusion, PANDAR dysregulation is a newly identified mechanism determining the early senescence of APCs from individuals with obesity, which worsens along the progression toward T2D. In the future, PANDAR targeting may represent a valuable strategy to delay this progression.
- 27 May 2022
- Published by Springer Nature in EMBO Reports
- Vol. 23 (7) , e52990
Glyoxalase 1 knockdown induces age‐related β‐cell dysfunction and glucose intolerance in mice
Tight control of glycemia is a major treatment goal for type 2 diabetes mellitus (T2DM). Clinical studies indicated that factors other than poor glycemic control may be important in fostering T2DM progression. Increased levels of methylglyoxal (MGO) associate with complications development, but its role in the early steps of T2DM pathogenesis has not been defined. Here, we show that MGO accumulation induces an age‐dependent impairment of glucose tolerance and glucose‐stimulated insulin secretion in mice knockdown for glyoxalase 1 (Glo1KD). This metabolic alteration associates with the presence of insular inflammatory infiltration (F4/80‐positive staining), the islet expression of senescence markers, and higher levels of cytokines (MCP‐1 and TNF‐α), part of the senescence‐activated secretory profile, in the pancreas from 10‐month‐old Glo1KD mice, compared with their WT littermates. In vitro exposure of INS832/13 β‐cells to MGO confirms its casual role on β‐cell dysfunction, which can be reverted by senolytic treatment. These data indicate that MGO is capable to induce early phenotypes typical of T2D progression, paving the way for novel prevention approaches to T2DM.
- 27 May 2022
- Published by Springer Nature in EMBO Reports
- Vol. 23 (7) , e52990
Glyoxalase 1 knockdown induces age‐related β‐cell dysfunction and glucose intolerance in mice
Tight control of glycemia is a major treatment goal for type 2 diabetes mellitus (T2DM). Clinical studies indicated that factors other than poor glycemic control may be important in fostering T2DM progression. Increased levels of methylglyoxal (MGO) associate with complications development, but its role in the early steps of T2DM pathogenesis has not been defined. Here, we show that MGO accumulation induces an age‐dependent impairment of glucose tolerance and glucose‐stimulated insulin secretion in mice knockdown for glyoxalase 1 (Glo1KD). This metabolic alteration associates with the presence of insular inflammatory infiltration (F4/80‐positive staining), the islet expression of senescence markers, and higher levels of cytokines (MCP‐1 and TNF‐α), part of the senescence‐activated secretory profile, in the pancreas from 10‐month‐old Glo1KD mice, compared with their WT littermates. In vitro exposure of INS832/13 β‐cells to MGO confirms its casual role on β‐cell dysfunction, which can be reverted by senolytic treatment. These data indicate that MGO is capable to induce early phenotypes typical of T2D progression, paving the way for novel prevention approaches to T2DM.